Altimmune, Inc. 8-K

What Happened Altimmune, Inc. announced by Form 8‑K that its 2026 Annual Meeting of Stockholders will be held on Thursday, April 16, 2026 (expected to be virtual). The company set the record date for voting at the close of business on Friday, March 13, 2026. The filing was signed by Gregory Weaver, Chief Financial Officer, on February 3, 2026.

Key Details

• 2026 Annual Meeting date: April 16, 2026 (expected virtual meeting).
• Record date for voting eligibility: close of business on March 13, 2026.
• Deadline for shareholder proposals under SEC Rule 14a-8 (to be included in the proxy): must be received by the Corporate Secretary at 910 Clopper Road, Suite 201S, Gaithersburg, MD 20878 by February 13, 2026.
• Other deadlines: director nominations or proposals under the company bylaws also due by February 13, 2026; notices required under the universal proxy rules (Rule 14a-19) due by February 15, 2026.
• The date change differs by more than 30 days from the 2025 meeting (held September 25, 2025), prompting the company to set these deadlines.

Why It Matters These dates determine who can vote at the meeting and the cutoffs for submitting shareholder proposals or director nominations. Retail investors who want to submit proposals, nominate directors, or solicit proxies should note the February deadlines and the March 13 record date to ensure participation. The company’s expectation of a virtual meeting is consistent with prior years and affects how shareholders will attend and vote.